Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and progression to blast phase, with the greatest risk conferred by triple-negative status. Subclonal mutations, including mutations in high–molecular risk (HMR) genes, such as ASXL1, EZH2, IDH1/2, and SRSF2 have also been...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Spiegel, Jay Y., McNamara, Caroline, Kennedy, James A., Panzarella, Tony, Arruda, Andrea, Stockley, Tracy, Sukhai, Mahadeo, Thomas, Mariam, Bartoszko, Justyna, Ho, Jenny, Siddiq, Nancy, Maze, Dawn, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Yee, Karen, Claudio, Jamie, Devlin, Rebecca, Minden, Mark D., Kamel-Reid, Suzanne, Gupta, Vikas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728340/
https://ncbi.nlm.nih.gov/pubmed/29296819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009530
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados